Combining AFP and C-Reactive Protein (CRP) serum levels has been suggested as an scoring system to predict clinical responses and survival in advanced HCC patients treated with Atezo/Bev therapy (24, 25). This evidence concerns the gene CRP and hepatocellular carcinoma.